493 related articles for article (PubMed ID: 19733014)
1. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
[TBL] [Abstract][Full Text] [Related]
2. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
3. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
4. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.
Yoo S; Wu QJ; Lee WR; Yin FF
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):935-42. PubMed ID: 20044214
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer.
Di Muzio N; Fiorino C; Cozzarini C; Alongi F; Broggi S; Mangili P; Guazzoni G; Valdagni R; Calandrino R; Fazio F
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):392-8. PubMed ID: 19056184
[TBL] [Abstract][Full Text] [Related]
11. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
Hysing LB; Skorpen TN; Alber M; Fjellsbø LB; Helle SI; Muren LP
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1496-503. PubMed ID: 18538493
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients.
Bayouth JE; Pena J; Culp L; Brack C; Sanguineti G
Med Dosim; 2008; 33(3):180-90. PubMed ID: 18674682
[TBL] [Abstract][Full Text] [Related]
13. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
14. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of margins in pelvic lymph nodes and prostate radiotherapy and the impact of bladder and rectum on prostate position.
Marnouche EA; Hadadi K; Abdelhak M; Benlemlih M; Hommadi M; Zaghba N; Andaloussi Saghir K; Elmarjany M; Sifat H; Mansouri H
Cancer Radiother; 2021 Apr; 25(2):161-168. PubMed ID: 33454191
[TBL] [Abstract][Full Text] [Related]
16. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
17. Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer.
Müller AC; Eckert F; Paulsen F; Zips D; Stenzl A; Schilling D; Alber M; Bares R; Martus P; Weckermann D; Belka C; Ganswindt U
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):263-71. PubMed ID: 26853335
[TBL] [Abstract][Full Text] [Related]
18. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
19. Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
Reis Ferreira M; Khan A; Thomas K; Truelove L; McNair H; Gao A; Parker CC; Huddart R; Bidmead M; Eeles R; Khoo V; van As NJ; Hansen VN; Dearnaley DP
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1234-1242. PubMed ID: 28939224
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity.
Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N
Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]